PCOM2 - The Physician Communication Intervention, Version 2.0
Part of paid clinical trials in Aurora, Colorado.
- Sponsor
- University of Colorado, Denver
- Study ID
- NCT05336240
- Status
- Recruiting
Conditions
- HPV Infection
- Preventive Health Services
Eligibility Criteria
- Sex
- ALL
- Age
- 9 Years - 17 Years
- Healthy Volunteers
- Not accepted
Interventions
- Physician Communication 2 Virtual (PCOM2-virtual) — BEHAVIORALThe PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. While this provider communication technique previously showed success in increasing HPV vaccination uptake, it is neither easy to disseminate nor sustainable due to it's nature of direct, intensive in-person training. Therefore, the intervention is to compare the standard-PCOM intervention to a new, PCOM2 intervention, that will be adapted virtually.
- Physician Communication Standard (PCOM-standard) — BEHAVIORALThe PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. PCOM-standard will be conducted in-person with providers.
Study Details
Poor quality of primary care providers' vaccine recommendations lead to low adolescent human papillomavirus vaccination rates and hundreds of thousands of adolescents unnecessarily at risk for HPV-associated cancers and diseases. Though a previous provider communication intervention, called PCOM, was found to be effective for increasing adolescent HPV vaccination in primary care, its dissemination is limited by the need for significant research team involvement to teach providers how to use the intervention's components. To address this, investigators propose to develop and test a virtual version of PCOM, use mixed methods to assess contextual factors affecting its use compared to the original PCOM intervention, and develop an optimized version of PCOM for broad dissemination to increase adolescent HPV vaccination nationally.
Key Dates
- Start date
- Nov 15, 2023
- Status verified
- Aug 2024
- Primary completion
- Dec 31, 2025
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 120 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Active Comparator: PCOM Standard ArmProviders in participating in the PCOM-standard intervention will be trained on optimizing an in-person provider communication technique about HPV vaccination by training primary care providers in a 2-step verbal communication process: 1) to start the HPV vaccine discussion using a "presumptive" format, and 2) to use motivational interviewing (MI) techniques to address parental vaccine hesitancy.
- Experimental: PCOM2 Virtual ArmProviders participating in the PCOM2-virtual arm will receive training on this communication method through an adapted virtual model of PCOM-standard. PCOM2-Virtual intervention will result in a "shelf ready" intervention and associated "User Manual" that can be easily incorporated into practices broadly to improve the practice's adolescent HPV vaccination rates. PCOM-Virtual arm will then be compared to that of the original PCOM-standard intervention in its efficacy for increasing HPV vaccination among adolescents.
Primary Outcome Measure
HPV vaccination initiation status in 11-12 year olds [ Time Frame: Adolescent vaccination initiation status will be assessed among all "active" (seen in the last 12 months) 11 to 12-year-old patients at each practice during the last 12 months of the 24 month intervention period ]
Central Contacts
- Christine Spina, MSPH303.724.0906
- Julian Dedeaux
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Colorado Anschutz Medical Campus | Aurora | Colorado | 80045 | Sean O'Leary, MD, MPH (PRINCIPAL_INVESTIGATOR) Gretchen Homan, MD, FAAP (SUB_INVESTIGATOR) |
| University of Kansas Medical Center | Wichita | Kansas | 67208 | Evelyn English Gretchen Homan, MD, FAAP (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Aurora, CO
Related Studies
- Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)PHASE2 · Recruiting · Frantz Viral Therapeutics, LLC · Fort Myers, Florida
- Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)PHASE4 · Recruiting · The University of Texas Medical Branch, Galveston · Galveston, Texas
- Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)PHASE2 · Recruiting · Frantz Viral Therapeutics, LLC · Fort Myers, Florida
- Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+PHASE2 · Not Yet Recruiting · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Birmingham, Alabama